Korea Kolma to enter pharmaceutical business.

Published: 2004-11-02 06:56:00

Updated: 2004-11-02 06:56:00

Korea Kolma declared a pharmaceutical business entry with their long accumulated technologies in the areas of the cosmetic raw material development and its finished product manufacture.

President Yoon Dong-han of Kolma said "The future enterprise functions may converge into the two areas, nam...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK